A Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion
A Randomized, Controlled, Double-Blind, Multi-center Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Yujia Song
- Phone Number: +8615640506016
- Email: songyujia@jeyoupharma.com
Study Locations
-
-
-
Beijing, China, 100017
- Cancer Hospital, Chinese Academy of Medical Sciences
-
Contact:
- Jie Wang
- Phone Number: +8613910704669
- Email: zlhuxi@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants with advanced solid tumors diagnosed by histopathology or cytopathology.
- Moderate to large pleural effusions require intervention.
- ECOG performance status: 0 to 2.
- Life expectancy ≥ 3 months
- Adequate organ function.
- The serum pregnancy test of female participants of childbearing potential should be negative within 7 days prior to enrollment and must not be breastfeeding. With a fertile female/male must agree to use medically accepted non-pharmacological contraception during the study and for 6 months after the last dose.
Exclusion Criteria:
- Bilateral pleural effusion or concurrent peritoneal effusion, or concurrent pericardial effusion.
- Pleural effusion is either encapsulated or severely separated; Or merge with chylothorax; Or combined with infectious pleural effusion.
- Known allergies to the study drug or its excipient components.
- Have participated in other clinical trials within 28 days prior to randomization.
- Major surgery within 28 days prior to randomization.
- Central nervous system metastatic disease, leptomeningeal disease, or cord compression.
- Clinical unstable or uncontrolled concomitant cardiovascular, pulmonary, hepatic, renal or seizures diseases.
- Active infections that require systemic treatment.
- Have a history of organ transplantation.
- Any further condition which, in the opinion of the Investigator, the participant is not suitable in the present study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm A
JMKX000197
|
Intrapleural administration
|
|
Experimental: Arm B
JMKX000197
|
Intrapleural administration
|
|
Active Comparator: Arm C
Cisplatin
|
Intrapleural administration
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Puncture/drainage - Free Survival (PuFS)
Time Frame: From the date of chest tube removal after the last dose of treatment until the date of next puncture /drainage or date of death from any cause, whichever come first, up to approximately 24 months
|
From the date of chest tube removal after the last dose of treatment until the date of next puncture /drainage or date of death from any cause, whichever come first, up to approximately 24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Overall survival (OS)
Time Frame: Up to approximately 24 months
|
Up to approximately 24 months
|
|
Pleural effusion overall response (ORR)
Time Frame: Up to approximately 24 months
|
Up to approximately 24 months
|
|
AEs or SAEs
Time Frame: Up to approximately 29 days
|
Up to approximately 29 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jie Wang, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Respiratory Tract Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Pleural Neoplasms
- Pleural Diseases
- Pleural Effusion
- Pleural Effusion, Malignant
- Myeloproliferative Disorder, Chronic, with Eosinophilia
- Inorganic Chemicals
- Chlorine Compounds
- Nitrogen Compounds
- Platinum Compounds
- Cisplatin
Other Study ID Numbers
Other Study ID Numbers
- JMKX000197-MPE201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.